Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117812625 | 11781262 | 5 | F | 20110819 | 20160719 | 20151126 | 20160727 | EXP | JP-ASTRAZENECA-2015SF13110 | ASTRAZENECA | KUSAKA K, ET AL. THE EFFICACY AND SAFETY OF GEFITINIB IN ELDERLY PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER. JAPANESE JOURNAL OF LUNG CANCER 2016; 56(3):177-182. | 26268.00 | DY | M | Y | 47.00000 | KG | 20160727 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117812625 | 11781262 | 1 | PS | IRESSA | GEFITINIB | 1 | Oral | 18250 | MG | Y | U | 0 | 250 | MG | TABLET | QD | |||
| 117812625 | 11781262 | 2 | SS | IRESSA | GEFITINIB | 1 | Oral | 18250 | MG | Y | U | 0 | 250 | MG | TABLET | QOD | |||
| 117812625 | 11781262 | 3 | C | THYRADIN S | LEVOTHYROXINE SODIUM | 1 | Oral | 0 | 50 | UG | TABLET | QD | |||||||
| 117812625 | 11781262 | 4 | C | PRIMPERAN | METOCLOPRAMIDE HYDROCHLORIDE | 1 | Oral | 0 | 5 | MG | TABLET | TID | |||||||
| 117812625 | 11781262 | 5 | C | GASMOTIN | MOSAPRIDE CITRATE | 1 | Oral | 0 | 5 | MG | TABLET | TID | |||||||
| 117812625 | 11781262 | 6 | C | RESPLEN | EPRAZINONE | 1 | Oral | 0 | 30 | MG | TABLET | TID | |||||||
| 117812625 | 11781262 | 7 | C | CALCIUM LACTATE HYDRATE | CALCIUM LACTATE | 1 | Oral | 0 | 1 | G | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 117812625 | 11781262 | 1 | Lung adenocarcinoma |
| 117812625 | 11781262 | 2 | Lung adenocarcinoma |
| 117812625 | 11781262 | 3 | Hypothyroidism |
| 117812625 | 11781262 | 4 | Nausea |
| 117812625 | 11781262 | 5 | Nausea |
| 117812625 | 11781262 | 6 | Cough |
| 117812625 | 11781262 | 7 | Hypocalcaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 117812625 | 11781262 | HO |
| 117812625 | 11781262 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 117812625 | 11781262 | Cough | |
| 117812625 | 11781262 | Decreased appetite | |
| 117812625 | 11781262 | Lung disorder | |
| 117812625 | 11781262 | Pruritus | |
| 117812625 | 11781262 | Rash |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 117812625 | 11781262 | 1 | 20110805 | 20111005 | 0 | |
| 117812625 | 11781262 | 2 | 20111006 | 20111026 | 0 | |
| 117812625 | 11781262 | 3 | 20111101 | 0 | ||
| 117812625 | 11781262 | 4 | 20111101 | 0 | ||
| 117812625 | 11781262 | 5 | 20111101 | 0 | ||
| 117812625 | 11781262 | 6 | 20110916 | 20111101 | 0 | |
| 117812625 | 11781262 | 7 | 20111101 | 0 |